-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62

Benzinga·05/26/2026 12:56:13
Listen to the news
Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $44 to $62.